JP2022542431A5 - - Google Patents
Info
- Publication number
- JP2022542431A5 JP2022542431A5 JP2022506359A JP2022506359A JP2022542431A5 JP 2022542431 A5 JP2022542431 A5 JP 2022542431A5 JP 2022506359 A JP2022506359 A JP 2022506359A JP 2022506359 A JP2022506359 A JP 2022506359A JP 2022542431 A5 JP2022542431 A5 JP 2022542431A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- variable region
- chain variable
- multispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880347P | 2019-07-30 | 2019-07-30 | |
| US62/880,347 | 2019-07-30 | ||
| PCT/US2020/070334 WO2021022304A2 (en) | 2019-07-30 | 2020-07-30 | MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542431A JP2022542431A (ja) | 2022-10-03 |
| JP2022542431A5 true JP2022542431A5 (https=) | 2023-08-08 |
Family
ID=72145539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506359A Pending JP2022542431A (ja) | 2019-07-30 | 2020-07-30 | 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230374130A1 (https=) |
| EP (1) | EP4004050A2 (https=) |
| JP (1) | JP2022542431A (https=) |
| CN (2) | CN114341186B (https=) |
| CA (1) | CA3146341A1 (https=) |
| WO (1) | WO2021022304A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022253248A1 (zh) * | 2021-06-02 | 2022-12-08 | 启愈生物技术(上海)有限公司 | 抗cd3抗体变异体、融合蛋白及应用 |
| CN117940460A (zh) * | 2021-09-08 | 2024-04-26 | 上海齐鲁制药研究中心有限公司 | 双特异性抗原结合分子及其应用 |
| CN116253802A (zh) | 2021-12-10 | 2023-06-13 | 苏州泽璟生物制药股份有限公司 | 包含lrrc15抗原结合结构域的多特异性t细胞接合剂 |
| WO2024005713A1 (en) * | 2022-06-27 | 2024-01-04 | Scg Cell Therapy Pte. Ltd. | Bispecific antibodies for hbv surface antigen（hbsag）and cd3 and uses thereof |
| CA3261708A1 (en) * | 2022-08-09 | 2024-02-15 | Qlsf Biotherapeutics, Inc. | ANTIBODIES BINDING TO CLEC12A |
| WO2024081729A2 (en) * | 2022-10-12 | 2024-04-18 | Mythic Therapeutics, Inc. | Lrrc-15-binding protein constructs and uses thereof |
| CN120051491A (zh) | 2022-11-01 | 2025-05-27 | 上海齐鲁制药研究中心有限公司 | 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用 |
| WO2025064369A1 (en) * | 2023-09-18 | 2025-03-27 | Modernatx, Inc. | Humanized anti-cd3 binding molecules and uses thereof |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025201242A1 (en) * | 2024-03-25 | 2025-10-02 | Tavotek Biotherapeutics (Hong Kong) Limited | Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US20050239700A1 (en) * | 2003-10-14 | 2005-10-27 | Biogen Idec Inc. | Treatment of cancer using antibodies to LRRC15 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| PT3904391T (pt) | 2010-03-10 | 2024-10-14 | Genmab As | Anticorpos monoclonais contra c-met |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| KR102211837B1 (ko) * | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| JP2016514676A (ja) | 2013-03-15 | 2016-05-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 四価二重特異性抗体 |
| US10259887B2 (en) * | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| DK3310814T5 (da) * | 2015-06-16 | 2024-10-07 | Hoffmann La Roche | Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse |
| SI3331910T1 (sl) * | 2015-08-03 | 2020-07-31 | Engmab Sarl | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) |
| AU2016365114A1 (en) | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| AU2016365117A1 (en) * | 2015-11-30 | 2018-05-31 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| PE20241349A1 (es) * | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
-
2020
- 2020-07-30 WO PCT/US2020/070334 patent/WO2021022304A2/en not_active Ceased
- 2020-07-30 CN CN202080061357.4A patent/CN114341186B/zh active Active
- 2020-07-30 CA CA3146341A patent/CA3146341A1/en active Pending
- 2020-07-30 EP EP20758074.7A patent/EP4004050A2/en not_active Withdrawn
- 2020-07-30 CN CN202510512319.0A patent/CN120842421A/zh active Pending
- 2020-07-30 JP JP2022506359A patent/JP2022542431A/ja active Pending
- 2020-07-30 US US17/588,086 patent/US20230374130A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542431A5 (https=) | ||
| JP7853992B2 (ja) | クローディン１８ａ２及びｃｄ３に対する二重特異性抗体及びその使用 | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP6721590B2 (ja) | 多重特異性抗体 | |
| JP2023538945A5 (https=) | ||
| JP2021508458A (ja) | Ｒｏｒ１特異性抗原結合分子 | |
| JP2021534096A5 (https=) | ||
| JP2024532485A5 (https=) | ||
| JP2021512630A5 (https=) | ||
| TW202227491A (zh) | 抗ｒｏｒ１抗體及相關雙特異性結合蛋白 | |
| JP2023518134A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| CN106456760B (zh) | 人源化的抗-Tau(pS422)抗体脑穿梭物及其应用 | |
| JP2010500876A5 (https=) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2018503380A5 (https=) | ||
| MX2014000816A (es) | Molecula fv de union de antigeno multivalente. | |
| JP2024541048A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2021522347A5 (https=) | ||
| JP2021511782A (ja) | 安定化された免疫グロブリンドメイン | |
| JP2020502233A5 (https=) | ||
| JP2021500873A (ja) | システイン操作された抗原結合分子 | |
| JP2024001073A5 (https=) |